Abstracts Archive - Page 1831 of 2425 - ACR Meeting Abstracts

Abstract Number: 2130 • 2015 ACR/ARHP Annual Meeting
Primary Prevention of Myocardial Infarction in Rheumatoid Arthritis Using Low-Dose Aspirin: A Case-Crossover Study
Josefina Durán Santa Cruz¹, Yuqing Zhang² and David T. Felson³, ¹Department of Rheumatology, Pontificia Universidad Católica de Chile School of Medicine, Santiago, Chile, ²Clinical Epidemilogy and Training Unit, Boston University School of Medicine, Boston, MA, ³Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Subjects with rheumatoid arthritis (RA) are at a higher risk of developing cardiovascular (CV) disease which is the leading cause of death in subjects…
Abstract Number: 2131 • 2015 ACR/ARHP Annual Meeting
Younger Age and Female Gender Are the Main Determinants of Underestimation of Cardiovascular Risk in Rheumatoid Arthritis Patients
Calin Popa^1,2, Alexander Rennings³, Alfons A. den Broeder⁴, Frank H.J. van den Hoogen⁴, Inger L. Meek¹ and Jaap Fransen¹, ¹Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Rheumatology, Bernhoven Hospital, Uden, Netherlands, ³Internal Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁴Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) patients have an increased cardiovascular (CV) risk. Current algorithms generally underestimate the risk in these patients [1]. In a meta-analysis, we…
Abstract Number: 2132 • 2015 ACR/ARHP Annual Meeting
Monocarboxylate Transporter 4, Associated with the Acidification of Synovial Fluid, Is a Novel Therapeutic Target for Inflammatory Arthritis
Wataru Fujii¹, Eishi Ashihara², Hidetake Nagahara³, Yuji Kukida¹, Takahiro Seno^1,4, Aihiro Yamamoto¹, Masataka Kohno¹, Ryo Oda⁵, Daigo Taniguchi⁶, Hiroyoshi Fujiwara⁵, Tsunao Kishida⁷, Osam Mazda⁷ and Yutaka Kawahito¹, ¹Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, ²Department of Clinical and Translational Physiology, Kyoto Pharmaceutical University, Kyoto, Japan, ³Department of Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, ⁴Department of Rheumatic Diseases and Joint Function, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, ⁵Department of Orthopaedics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, kyoto, Japan, ⁶Department of Orthopaedics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, ⁷Department of Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
Background/Purpose: Synovial fluid pH is decreased in patients with rheumatoid arthritis (RA)are unclear. Here, we examined the mechanism by which synovial fluid pH is regulated…
Abstract Number: 2133 • 2015 ACR/ARHP Annual Meeting
Receptor Protein Tyrosine Phosphatase Alpha Enhances Rheumatoid Synovial Fibroblast Signaling and Promotes Arthritis in Mice
Stephanie M. Stanford¹, Mattias N. D. Svensson¹, Cristiano Sacchetti¹, Caila A. Pilo¹, Dennis J. Wu¹, William B. Kiosses², Annelie Hellvard³, Brith Bergum³, German R. Aleman Muench¹, Christian Elly¹, Yun-Cai Liu¹, Jeroen den Hertog^4,5, Ari Elson⁶, Jan Sap⁷, Piotr Mydel³, David L. Boyle⁸, Maripat Corr⁸, Gary S. Firestein⁸ and Nunzio Bottini¹, ¹Cellular Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, ²The Scripps Research Institute, La Jolla, CA, ³Clinical Science, Broegelmann Research Laboratory, Bergen, Norway, ⁴Hubrecht Institute-Koninklijke Nederlands Akademie van Wetenschappen and University Medical Center Utrecht, Utrecht, Netherlands, ⁵Institute of Biology Leiden, Leiden, Netherlands, ⁶Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel, ⁷Epigenetics and Cell Fate, Université Paris Diderot Sorbonne Paris Cité, Paris, France, ⁸Division of Rheumatology, Allergy and Immunology, University of California at San Diego School of Medicine, La Jolla, CA
Background/Purpose: Rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) promote disease pathogenesis by aggressively invading the joint extracellular matrix. The focal adhesion kinase (FAK) signaling pathway is…
Abstract Number: 2134 • 2015 ACR/ARHP Annual Meeting
Metabolic Reprogramming in the Inflamed Joint Inhibits Pro-Inflammatory Mechanisms
Monika Biniecka¹, Mary Canavan¹, Chin Teck Ng², Wei Gao¹, Thomas Smith³, Trudy McGarry⁴, Douglas J. Veale⁵ and Ursula Fearon⁴, ¹St. Vincent's University Hospital, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, Dublin, Ireland, ²Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia, ³Department of Endocrinology, St Vincent’s University Hospital, Dublin, Ireland, ⁴St. Vincent's University Hospital, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, Dublin 4, Ireland, ⁵St Vincent's University Hospital, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, Dublin 4, Ireland
Background/Purpose: To examine the relationship between synovial hypoxia, cellular bioenergetics and mitochondrial dysfunction with synovial inflammation. Methods: Primary RASFC were cultured with 3% hypoxia, DMOG…
Abstract Number: 2135 • 2015 ACR/ARHP Annual Meeting
miRNA-223 Delivery to Synovial Fibroblasts Via Monocyte-Derived Extracellular Vesicles Promotes Their Proliferation
Florian M.P. Meier¹, Derek S. Gilchrist¹, Derek Baxter², Diane Vaughan¹, Margaret Mullin³, David W. McCarey⁴, Pawel Herzyk⁵, Julie Galbraith⁵, Donna McIntyre¹, Russka Shumnalieva⁶, Ulf Müller-Ladner⁷, Iain B. McInnes⁸ and Mariola Kurowska-Stolarska¹, ¹Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ²Department of Rheumatology, University Hospital Ayr, Ayr, United Kingdom, ³School of Life Sciences, University of Glasgow, Glasgow, United Kingdom, ⁴Glasgow Royal Infirmary, Glasgow, United Kingdom, ⁵Polyomics Facility, Institute of Molecular Cell and Systems Biology, University of Glasgow, Glasgow, United Kingdom, ⁶Department of Internal Medicine, Clinic of Rheumatology, Sofia, Bulgaria, ⁷Internal Medicine and Rheumatology, Justus-Liebig-University of Giessen, Kerckhoff-Klinik, Bad Nauheim, Germany, ⁸Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Recently, it was shown that extracellular vesicles (EV) convey microRNAs (miR) from platelets to endothelial cells1and regulate recipient cell gene expression. Interaction of synovial…
Abstract Number: 2136 • 2015 ACR/ARHP Annual Meeting
Identification of Synovial Fibroblast Subsets That Define Pathology in Rheumatoid Arthritis
Fumitaka Mizoguchi¹, Kamil Slowikowski^2,3, Sook Kyung Chang¹, Deepak A. Rao⁴, Hung Nguyen¹, Erika H. Noss⁵, Brandon E. Earp⁶, Philip E. Blazar⁶, John Wright⁶, Barry P. Simmons⁶, Nir Hacohen^7,8,9, Peter A. Nigrovic^1,10, Soumya Raychaudhuri^2,3,11 and Michael B. Brenner¹, ¹Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Divisions of Rheumatology and Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Medical and Population Genetics Program, Broad Institute of MIT and Harvard, Cambridge, MA, ⁴Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Divison of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶Department of Orthopedic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁷Broad Institute of MIT and Harvard, Cambridge, MA, ⁸Massachusetts General Hospital, Charlestown, MA, ⁹Harvard Medical School, Boston, MA, ¹⁰Division of Immunology, Boston Children's Hospital, Boston, MA, ¹¹Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Synovial fibroblasts play crucial roles in the pathogenesis of rheumatoid arthritis (RA). They expand as part of the pannus, mediate degradation of cartilage, amplify…
Abstract Number: 2137 • 2015 ACR/ARHP Annual Meeting
Critical Role of Fibroblast-like Synoviocytes Glycolytic Metabolism in Rheumatoid Arthritis
Ricard Garcia-Carbonell¹, Ajit Divakaruni¹, Alessia Lodi², Ildefonso Vicente-Suarez³, Hilde Cheroutre⁴, Gerry Boss¹, Arindam Saha¹, Stefano Tiziani⁵, Anne Murphy⁶, Gary S. Firestein⁷ and Monica Guma⁶, ¹University of California, San Diego, La Jolla, CA, ²nutritional Sciences, University of Texas at Austin, Austin, TX, ³LIAI, La Jolla, CA, ⁴Autoimmune Research, LIAI, La Jolla, CA, ⁵Nutritional Sciences, University of Texas at Austin, Austin, TX, ⁶Pharmacology, University of California, San Diego, La Jolla, CA, ⁷Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA
Background/Purpose: Glucose metabolism is altered not only in tumor cell growth but also in immune cells on activation. However, little is known about glucose metabolism…
Abstract Number: 2138 • 2015 ACR/ARHP Annual Meeting
Safety and Efficacy Results of a Phase 2, Double-Blind, Placebo-Controlled Clinical Study of Duvelisib with Background Methotrexate (MTX) in Adults with Moderate-to-Severe Rheumatoid Arthritis (RA)
Richard Leff¹, Sunil Kumar², Natalia Nikulenkova³, Igor Kaidashev⁴, Kerstin Allen⁵, Joi Dunbar⁶, Howard Stern⁷, Julian Adams⁶ and Michael Weinblatt⁸, ¹Clinical Research, Infinity Pharmaceuticals, Inc., Cambridge, MA, ²Centre for Clinical Research and Effective Practice (CCRep), Auckland, New Zealand, ³State Budgetary Healthcare Institution of Vladimir Region, Regional Clinical Hospital, Vladimir, Russia, ⁴City Clinical Hospital #1 of Poltava City, Poltava, Ukraine, ⁵Biostatistics, Infinity Pharmaceuticals, Inc., Cambridge, MA, ⁶Infinity Pharmaceuticals, Inc., Cambridge, MA, ⁷Translational Science, Infinity Pharmaceuticals, Inc., Cambridge, MA, ⁸Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Duvelisib is a potent, oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-δ,γ being developed for hematologic malignancies, and was also explored in early phase studies in…
Abstract Number: 2139 • 2015 ACR/ARHP Annual Meeting
Results of a Phase 1b/2a Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XmAb®5871 in Patients with Rheumatoid Arthritis (RA)
Debra Zack¹, Maria Jaraczewska Baumann², Mariusz Korkosz³, Gabriella Suljok⁴, Petr Sramek⁵, Bernadette Rojkovich⁶, Stafan Daniluk⁷, Janos Bartalos⁸ and Paul Foster¹, ¹Xencor, Inc., San Diego, CA, ²NZOZ Centrum Medyczne HCP, Poznan, Poland, ³Malopolskie Centrum Medyczne, The University Hospital in Krakow, Krakow, Poland, ⁴Drug Research Center Ltd., Baltonfüred, Hungary, ⁵PRA CZ, Praha, Czech Republic, ⁶Polyclinic of the Hospitaller Brothers of St John of God, Budapest, Hungary, ⁷NZOZ Center of Osteoporosis and Osteoarticular Diseases, Bialystok, Poland, ⁸PRA Hungary Ltd, Budapest, Hungary
Background/Purpose: XmAb®5871 is a humanized Fc engineered monoclonal antibody that binds to the B cell restricted surface antigen CD19 and has enhanced Fc binding to…
Abstract Number: 2140 • 2015 ACR/ARHP Annual Meeting
Drug Specific Risk and Associated Factors for Vasculitis-like Events in Patients Exposed to Tumour Necrosis Factor-Î± Inhibitor Therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Meghna Jani¹, William G Dixon², Lianne Kearsley-Fleet³, Ian N. Bruce^4,5, Hector Chinoy^6,7, Anne Barton^6,8, Mark Lunt⁹, Kath Watson³, Deborah P.M. Symmons¹, Kimme L. Hyrich³ and on behalf of the BSRBR-RA, ¹Centre for Musculoskeletal Research, University of Manchester, Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom, ²Manchester Academic Health Sciences Centre, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ³Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁴Stopford Building, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ⁵Central Manchester University Hospital NHS Foundation Trust and Manchester Academic Health Science Centre, NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom, ⁶Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ⁷NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom, ⁸NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester Foundation Trust and University of Manchester, Manchester Academy of Health Sciences, Manchester, United Kingdom, ⁹Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom
Background/Purpose: The association between TNF inhibitors (TNFis) and vasculitis-like events, possibly secondary to induction of autoantibodies, has been well reported. However, the incidence, drug-specific differences…
Abstract Number: 2141 • 2015 ACR/ARHP Annual Meeting
Risk of Cancer in Non-TNFi Biologics-Treated RA
Hjalmar Wadström¹, Johan Askling² and the ARTIS study group, ¹Clinical Epidemiology Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden, ²Clinical Epidemiology Unit and Rheumatology Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden
Background/Purpose: Immune incompetence may lower host surveillance against incipient tumours. Conversely, immune therapies have emerged as a promising therapeutic approach to cancer. Malignancies thus constitute…
Abstract Number: 2142 • 2015 ACR/ARHP Annual Meeting
Comparison of Interferon-y Release Assay Versus Tuberculin Skin Test in the Golimumab UC and the Golimumab SC Rheumatology (RA, PsA, and AS) Clinical Study Programs
Elizabeth C. Hsia^1,2, Neil Schluger³, John J. Cush⁴, Eric L. Matteson⁵, Stephen Xu¹, William Sandborn⁶, Paul Rutgeerts⁷ and Colleen Marano¹, ¹Janssen Research & Development, LLC, Spring House, PA, ²University of Pennsylvania, Philadelphia, PA, ³Columbia U College of Physicians & Surgeons, New York, NY, ⁴Baylor Research Institute, Dallas, TX, ⁵Division of Rheumatology, Department of Internal Medicine and Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁶Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, California, La Jolla, CA, ⁷University Hospital Gasthuisberg, Leuven, Belgium
Background/Purpose: Interferon-ƴ release assays (IGRAs) offer the possibility of an improved method to detect TB infections in pts with autoimmune disorders. Compare results of…
Abstract Number: 2143 • 2015 ACR/ARHP Annual Meeting
A Safety Analysis of Tofacitinib 5mg Twice Daily Administered As Monotherapy or in Combination with Background Conventional Synthetic Dmards in a Phase 3 Rheumatoid Arthritis Population
Alan J Kivitz¹, Boulos Haraoui², Jeffrey Kaine³, Vanessa Castellano⁴, Eustratios Bananis⁴, Carol A Connell⁵, Elaine Hoffman⁵ and Liza Takiya⁶, ¹Altoona Center for Clinical Research, Duncansville, PA, ²Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ³Sarasota Arthritis Research Center, Sarasota, FL, ⁴Pfizer Inc, Collegeville, PA, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). In Phase 3 (P3) studies, tofacitinib demonstrated safety and efficacy…
Abstract Number: 2144 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Different Dose Regimens of a Selective IL-23p19 Inhibitor (BI 655066) Compared with Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis with and without Psoriatic Arthritis
Kim Papp¹, Alan Menter², Howard Sofen³, Stephen Tyring⁴, Jean-Philippe Lacour⁵, Beate Berner⁶, Nathan Bennett⁷, Stella Aslanyan⁷, Mary Flack⁷ and Paul Scholl⁷, ¹Probity Clinical Research, Waterloo, ON, Canada, ²Baylor Research Institute, Dallas, TX, ³Dermatology Research Associates, Los Angeles, CA, ⁴Center for Clinical Studies, Houston, TX, ⁵Dermatology Department, Hôpital de L’Archet, Nice, France, ⁶Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, ⁷Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT
Background/Purpose: IL-23 is essential for the differentiation and maintenance of Th17 cells in psoriasis and psoriatic arthritis (PsA). We assessed the efficacy and safety of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].